GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Asset Turnover

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Asset Turnover : 0.00 (As of Mar. 2018)


View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Anthera Pharmaceuticals's Revenue for the three months ended in Mar. 2018 was $0.00 Mil. Anthera Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2018 was $6.24 Mil. Therefore, Anthera Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2018 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Anthera Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2018 was 181,741.18%. It is also linked to ROA % through Du Pont Formula. Anthera Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2018 was -494.97%.


Anthera Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Anthera Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anthera Pharmaceuticals Asset Turnover Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.12 - -

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anthera Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Anthera Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anthera Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Asset Turnover falls into.



Anthera Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Anthera Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2017 )/( (Total Assets (A: Dec. 2016 )+Total Assets (A: Dec. 2017 ))/ count )
=0/( (23.471+3.673)/ 2 )
=0/13.572
=0.00

Anthera Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2018 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2018 )/( (Total Assets (Q: Dec. 2017 )+Total Assets (Q: Mar. 2018 ))/ count )
=0/( (3.673+8.811)/ 2 )
=0/6.242
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Anthera Pharmaceuticals  (OTCPK:ANTH) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Anthera Pharmaceuticals's annulized ROE % for the quarter that ended in Mar. 2018 is

ROE %**(Q: Mar. 2018 )
=Net Income/Total Stockholders Equity
=-30.896/-0.017
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-30.896 / 0)*(0 / 6.242)*(6.242/ -0.017)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-367.1765
=ROA %*Equity Multiplier
=-494.97 %*-367.1765
=181,741.18 %

Note: The Net Income data used here is four times the quarterly (Mar. 2018) net income data. The Revenue data used here is four times the quarterly (Mar. 2018) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Anthera Pharmaceuticals's annulized ROA % for the quarter that ended in Mar. 2018 is

ROA %(Q: Mar. 2018 )
=Net Income/Total Assets
=-30.896/6.242
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-30.896 / 0)*(0 / 6.242)
=Net Margin %*Asset Turnover
= %*0
=-494.97 %

Note: The Net Income data used here is four times the quarterly (Mar. 2018) net income data. The Revenue data used here is four times the quarterly (Mar. 2018) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Anthera Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Executives
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr officer: Chief Medical Officer 10301 STELLA LINK HOUSTON TX 77025
Brian Mueller director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex director PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson officer: Chief Technology Officer 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson officer: Chief Regulatory Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle director C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington officer: Interim Chief Medical Officer 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin officer: Chief Medical Officer C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe officer: CFO and Chief Business Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines